Lentinan

DRUG3 trials

Sponsors

AJI Pharma USA, GlycaNova Norge AS

Conditions

HIV InfectionsHealthy

Phase 1

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

CompletedNCT00002098

AJI Pharma USAHIV Infections

Target: 50Updated: 2005-06-24

Dose Escalation Safety Study of MM-10-001 in Healthy Subjects

GlycaNova Norge ASHealthy

Start: 2008-02-29End: 2008-06-30Target: 50Updated: 2008-05-13

Phase 2

Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

AJI Pharma USAHIV Infections

Updated: 2005-06-24

Related Papers

The Effects of Orally Administered Beta-Glucan on Innate Immune Responses in Humans, a Randomized Open-Label Intervention Pilot-Study

PLoS ONE2014-09-3073 citations